WuXi AppTec

NAMSA announced plans to acquire WuXi AppTec's medical device testing operations in the U.S., including facilities in Minnesota and Georgia. The acquisition expands NAMSA's portfolio of clinical research and testing solutions for medtech companies.

WuXi AppTec plans to expand its facilities in San Diego, establishing a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing. The article does not specify investment amount or timeline.

STA Pharmaceutical, a subsidiary of WuXi AppTec, announced plans to expand its one-year-old Changzhou campus. The expansion will increase headcount from 200 to 300 scientists and reactor volume from 290 to 490 cubic meters in the short term, with eventual targets of 500 scientists and 1,500 cubic meters.